Roy Vagelos - Regeneron Pharmaceuticals Chairman of the Board

REGN -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  Chairman
Dr. P. Roy Vagelos, M.D., is an Chairman of the Board of the Company. Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck Co., Inc., a global pharmaceutical company. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos served on the board of directors of Theravance, Inc. through April 2010
Age: 88  Chairman Since 1995  Ph.D    
914 847-7000  www.regeneron.com
Vagelos is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Philosophical Society. During his tenure as Chairman of the Company and previously as Chairman and Chief Executive Officer of Merck, Dr. Vagelos developed an extensive understanding of the complex business, operational, scientific, regulatory, and commercial issues facing the pharmaceutical industry.

Management Efficiency

The company has return on total asset (ROA) of 11.38 % which means that it generated profit of $11.38 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 23.34 % meaning that it created $23.34 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 9 records

CHAIRMAN Since

G PrasadDr Reddys Laboratories Ltd
2014
Marry BrlasPerrigo Company Plc
2016
Joshua BogerVertex Pharmaceuticals Incorpor
2009
Michael McCallisterZoetis
2015
Gengchen HanOrigin Agritech Limited
2016
Joseph PapaPerrigo Company Plc
2015
Jeffrey LeidenVertex Pharmaceuticals Incorpor
2012
Satish ReddyDr Reddys Laboratories Ltd
2014
Yasheng YangOrigin Agritech Limited
2010

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

Currently Active Assets on Macroaxis

CAE   
Purchased few shares of
a day ago
Traded for 26.59
UNP   
Purchased few shares of
a day ago
Traded for 175.48
FEYE   
Purchased few shares of
a day ago
Traded for 17.11
PM   
Purchased few shares of
a day ago
Traded for 83.77
PSTG   
Purchased few shares of
a day ago
Traded for 20.19
Additionally take a look at Your Equity Center. Please also try Market Hitters module to find equities that experience drastic asymmetry in trading patters, price, volume, or investment outlook..
Search macroaxis.com